RTW's Yarrow to go public in reverse merger with Vyne Therapeutics
RTW 旗下的 Yarrow 将通过与 VYNE Therapeutics 的反向并购上市

Vyne Therapeutics will hand its Nasdaq spot to RTW’s Yarrow Bioscience in a reverse merger that will also bring a $200 million cash infusion into the biotech.
VYNE Therapeutics将通过反向并购把其纳斯达克席位交给RTW旗下的Yarrow Bioscience，同时也将为这家生物科技公司带来一笔2亿美元的现金注入。